Comparative Pharmacology
Head-to-head clinical analysis: BUMETANIDE versus URESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMETANIDE versus URESE.
BUMETANIDE vs URESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Urease inhibitor; reduces bacterial conversion of urea to ammonia, lowering urine pH and ammonia concentration.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Oral: 20 mg once daily. May increase to 40 mg once daily if needed after 4 weeks. Maximum: 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Clinical Note
moderateBumetanide + Digoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin."
Clinical Note
moderateBumetanide + Digitoxin
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
Clinical Note
moderateBumetanide + Deslanoside
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside."
Clinical Note
moderateBumetanide + Acetyldigitoxin
4-6 hours; prolonged in renal impairment (up to 12-15 hours in anuria).
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category A/B
Category C
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin."